MDT

97.97

-0.41%↓

VEEV

301.82

-1.22%↓

A

141.04

+1.79%↑

HQY

92.06

+4.03%↑

PHR.US

23.23

-0.43%↓

MDT

97.97

-0.41%↓

VEEV

301.82

-1.22%↓

A

141.04

+1.79%↑

HQY

92.06

+4.03%↑

PHR.US

23.23

-0.43%↓

MDT

97.97

-0.41%↓

VEEV

301.82

-1.22%↓

A

141.04

+1.79%↑

HQY

92.06

+4.03%↑

PHR.US

23.23

-0.43%↓

MDT

97.97

-0.41%↓

VEEV

301.82

-1.22%↓

A

141.04

+1.79%↑

HQY

92.06

+4.03%↑

PHR.US

23.23

-0.43%↓

MDT

97.97

-0.41%↓

VEEV

301.82

-1.22%↓

A

141.04

+1.79%↑

HQY

92.06

+4.03%↑

PHR.US

23.23

-0.43%↓

Search

Supernus Pharmaceuticals Inc

Închisă

SectorSănătate

47.87 -0.35

Rezumat

Modificarea prețului

24h

Curent

Minim

47.18

Maxim

48.2

Indicatori cheie

By Trading Economics

Venit

34M

22M

Vânzări

16M

165M

P/E

Medie Sector

42.009

37.257

Marjă de profit

13.598

Angajați

674

EBITDA

20M

38M

Recomandări

By TipRanks

Recomandări

Cumpărare

Prognoză pe 12 luni

-0.67% downside

Dividende

By Dow Jones

Următoarele câștiguri

3 nov. 2025

Statistici piață

By TradingEconomics

Capitalizare de piață

634M

2.7B

Deschiderea anterioară

48.22

Închiderea anterioară

47.87

Sentimentul știrilor

By Acuity

50%

50%

191 / 371 Clasament în Healthcare

Scor tehnic

By Trading Central

Încredere

Weak Bearish Evidence

Supernus Pharmaceuticals Inc Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

8 oct. 2025, 20:45 UTC

Câștiguri

Costco Wholesale Sales Climb in September, Early October

8 oct. 2025, 20:12 UTC

Principalele dinamici ale pieței
Achiziții, Fuziuni, Preluări

TaskUs Shares Fall After Holders Reject Take-Private Deal

8 oct. 2025, 16:39 UTC

Principalele dinamici ale pieței

Mining Shares Rise as Gold Prices Soar

8 oct. 2025, 23:45 UTC

Market Talk

Nikkei May Rise on Weaker Yen -- Market Talk

8 oct. 2025, 23:43 UTC

Market Talk

Gold Falls on Possible Profit-Taking -- Market Talk

8 oct. 2025, 23:18 UTC

Achiziții, Fuziuni, Preluări

JD Logistics to Finance Acquisition Using Internal Funds

8 oct. 2025, 23:17 UTC

Achiziții, Fuziuni, Preluări

JD Logistics to Buy On-Demand Delivery Services Business for US$270.0M

8 oct. 2025, 23:16 UTC

Achiziții, Fuziuni, Preluări

JD Logistics to Buy JD.com's On-Demand Delivery Services Business Dajiang and Dasheng

8 oct. 2025, 21:54 UTC

Market Talk
Câștiguri

James Hardie Could Beat Annual Earnings Goal -- Market Talk

8 oct. 2025, 21:30 UTC

Market Talk

Boab Metals Bull Delivers Second Upgrade in a Month -- Market Talk

8 oct. 2025, 21:26 UTC

Market Talk
Câștiguri

Transurban's 1Q Traffic Growth Beats Hopes -- Market Talk

8 oct. 2025, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

8 oct. 2025, 19:15 UTC

Market Talk

Geopolitical Risk Supports Gains in Oil Futures -- Market Talk

8 oct. 2025, 19:01 UTC

Market Talk

U.S. Natural Gas Futures Pull Back Ahead of Storage Data -- Market Talk

8 oct. 2025, 18:47 UTC

Market Talk

Coca-Cola North America Sales Buoy International Weakness -- Market Talk

8 oct. 2025, 18:46 UTC

Achiziții, Fuziuni, Preluări

TaskUs: Neither Party Will Be Required to Pay Termination Fee as Result of Planned Mutual Decision to Terminate

8 oct. 2025, 18:46 UTC

Achiziții, Fuziuni, Preluări

TaskUs Will Remain a Publicly Traded Co >TASK

8 oct. 2025, 18:46 UTC

Achiziții, Fuziuni, Preluări

TaskUs Does Not Plan to Convene Another Special Meeting of Stockholders >TASK

8 oct. 2025, 18:45 UTC

Achiziții, Fuziuni, Preluări

TaskUs Didn't Receive Votes Necessary to Approve Transaction Agreement With Affil of Blackstone >TASK

8 oct. 2025, 18:07 UTC

Market Talk

Mexico's Inflation Seen Edging Up in September -- Market Talk

8 oct. 2025, 16:20 UTC

Market Talk
Achiziții, Fuziuni, Preluări

Energy & Utilities Roundup: Market Talk

8 oct. 2025, 16:20 UTC

Market Talk

Basic Materials Roundup: Market Talk

8 oct. 2025, 16:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

8 oct. 2025, 15:57 UTC

Market Talk

Oil Rises Despite U.S. Crude Stockpiles Build -- Market Talk

8 oct. 2025, 15:56 UTC

Market Talk

Teck Resources' Chile Mine Issues Appear Transitory -- Market Talk

8 oct. 2025, 15:53 UTC

Market Talk

Argentine Sovereign Debt Seen as Attractive -- Market Talk

8 oct. 2025, 15:44 UTC

Achiziții, Fuziuni, Preluări

Staar Surgical: Broadwood's Proposal to Vote Down Merger Could Allow It to Take Control Without Paying Any Premium

8 oct. 2025, 15:44 UTC

Achiziții, Fuziuni, Preluări

Staar Surgical Board and Management Disagree With Recommendation Issued by Glass Lewis >STAA

8 oct. 2025, 15:43 UTC

Achiziții, Fuziuni, Preluări

STAAR Surgical Board Reiterates Unanimous Recommendation Holders Vote for Alcon Merger

8 oct. 2025, 15:42 UTC

Achiziții, Fuziuni, Preluări

Oracle Is a Buy-the-Dip Opportunity, Analyst Says. How the Stock Could Rise 23%. -- Barrons.com

Comparație

Modificare preț

Supernus Pharmaceuticals Inc Așteptări

Obiectiv de preț

By TipRanks

-0.67% jos

Prognoză pe 12 luni

Medie 47.75 USD  -0.67%

Maxim 63 USD

Minim 40 USD

În baza a 4 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruSupernus Pharmaceuticals Inc - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Cumpărare

4 ratings

2

Cumpărare

2

Păstrare

0

Vânzare

Scor tehnic

By Trading Central

31.35 / 32.36Suport & Rezistență

Termen scurt

Weak Bearish Evidence

Termen mediu

Bearish Evidence

Termen lung

Neutral Evidence

Sentiment

By Acuity

191 / 371 Clasament în Sănătate

Sentimentul știrilor

Neutral

Volatilitate

Sub medie

Volumul știrilor (RCV)

Sub medie

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

$

Despre Supernus Pharmaceuticals Inc

Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age. It also offers comprise Qelbree, a novel non-stimulant indicated for the treatment of attention-deficit hyperactivity disorder (ADHD) in adults and pediatric patients 6 years and older; APOKYN for the acute intermittent treatment of hypomobility or off episodes in patients with advanced Parkinson's Disease (PD); XADAGO for treating levodopa/carbidopa in patients with PD experiencing off episodes; MYOBLOC, a Type B toxin product indicated for the treatment of cervical dystonia and sialorrhea in adults; GOCOVRI for the treatment of dyskinesia in patients with PD; and Osmolex ER for the treatment of Parkinson's disease and drug-induced extrapyramidal reaction in adult patients. In addition, the company's product candidates include SPN-830, a late-stage drug/device combination product candidate for the treatment of off episodes in PD patients; SPN-817, a novel first-in-class selective acetylcholinesterase inhibitor, which is in Phase II clinical trials for the treatment of epilepsy; SPN-820, a product candidate in Phase II clinical trials for treating resistant depression; SPN-443, a preclinical product for the treatment of ADHD/CNS; and SPN-446 for narcolepsy and SPN-448 for the treatment of CNS which is in discovery stage. It markets and sells its products through pharmaceutical wholesalers, specialty pharmacies, and distributors. Supernus Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Rockville, Maryland.
help-icon Live chat